Tag: pipeline

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Caribou (CRBU) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Crocs (CROX) To Contact Him Directly To Discuss Their Options

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency

Discover the future of Cannabis-Induced Psychosis (CIP) with the latest Pipeline Insight 2025 report. Gain in-depth analysis of CIP therapeutic developments, from early to marketed stages, including collaboration trends, licensing deals, and clinical trials. Navigate key players, active projects, and market growth strategies within the evolving CIP landscape.

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- The ADVERTISING Club of New York, the industry's leading professional organization representing the advertising, media, marketing, and ad-tech industries is pleased to announce the appointment of five individuals to its Board of Directors. These appointments bring a wealth of experience and expertise to the organization as they rally around the mission to continue to educate, celebrate, and empower the industry.